Y-688, a new quinolone active against quinolone-resistant staphylococcus aureus: Lack of in vivo efficacy in experimental endocarditis

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 8, 1998, Pages 1889-1894

  Entenza, J M ^a   Marchetti, O ^a   Glauser, M P ^a   Moreillon, P ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

7 (3 AMINOMETHYL 3 FLUOROMETHYL 1 PYRROLIDINYL) 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; CIPROFLOXACIN; QUINOLONE DERIVATIVE; SPARFLOXACIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENDOCARDITIS; INTRAVENOUS DRUG ADMINISTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 0031879454     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.8.1889     Document Type: Article

References (28)

1. Blouin, R. A., L. A. Bauer, D. D. Miller, K. E. Record, and W. O. Griffen. 1982. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob. Agents Chemother. 21:575-580.
2. Borner, K., G. Höffken, H. Lode, P. Koeppe, C. Prinzing, P. Glatzel, R. Wiley, P. Olschewski, B. Sievers, and D. Reinitz. 1986. Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur. J. Clin. Microbiol. 5:179-186.
3. Chin, N. X., and H. C. Neu. 1984. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 25:319-326.
4. Cremieux, A. C., B. Maziere, J. M. Vallois, M. Ottaviani, A. Azancot, H. Raffoul, A. Bouvet, J. J. Pocidalo, and C. Carbon. 1989. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J. Infect. Dis. 159:938-944.
5. 4a. Crémieux, A. C., A. Saleh-Mghir, J. M. Vallois, M. Ottaviani, J. J. Pocidalo, and C. Carbon. 1991. Pattern and diffusion of three quinolones throughout infected cardiac vegetations studied by autoradiography, abstr. 357, p. 158. In Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
6. Entenza, J. M., M. Blatter, P. Francioli, M. P. Glauser, and P. Moreillon. 1996. Sparfloxacin treatment of experimental endocarditis due to ciprofloxacin-susceptible or laboratory-selected resistant methicillin-resistant Staphylococcus aureus, abstr. B-9, p. 23. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Entenza, J. M., M. Blatter, P. Francioli, M. P. Glauser, and P. Moreillon. 1994. Parenteral sparfloxacin compare with ceftriaxone in treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci. Antimicrob. Agents Chemother. 38:2683-2688.
8. Entenza, J. M., I. Caldelari, M. P. Glauser, P. Francioli, and P. Moreillon. 1997. Importance of genotypic and phenotypic tolerance in the treatment of experimental endocarditis due to Streptococcus gordonii. J. Infect. Dis. 175: 70-76.
9. Entenza, J. M., U. Fluckiger, M. P. Glauser, and P. Moreillon. 1994. Antibiotic treatment of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis. J. Infect. Dis. 170:100-109.
10. Entenza, J. M., J. Vouillamoz, M. Giddey, M. P. Glauser, and P. Moreillon. 1997. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 41:1662-1667.
11. Ferrero, L., B. Cameron, B. Manse, D. Lagneaux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13:641-653.
12. Flückiger, U., P. Francioli, J. Blaser, M. P. Glauser, and P. Moreillon. 1994. Role of amoxicillin serum level for successful prophylaxis of experimental endocarditis due to tolerant streptococci. J. Infect. Dis. 169:1397-1400.
13. Garcia-Rodriguez, J. A., J. E. Garcia, M. I. Garcia Garcia, M. J. Fresnadillo, I. Trujillano, and E. Garcia Sanchez. 1994. In vitro activity of four new fluoroquinolones. J. Antimicrob. Chemother. 34:53-64.
14. Goswitz, J. J., K. E. Willard, C. E. Fasching, and L. R. Peterson. 1992. Detection of gyrA mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing. Antimicrob. Agents Chemother. 36: 1166-1169.
15. Harnett, N., S. Brown, and C. Krishnan. 1991. Emergence of quinolone resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in Ontario. Antimicrob. Agents Chemother. 3:1911-1913.
16. Heraief, E., M. P. Glauser, and L. Freedmann. 1982. Natural history of aortic valve endocarditis in rats. Infect. Immun. 37:127-131.
17. Kaatz, G. W., S. M. Seo, and C. A. Ruble. 1993. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 37:1086-1094.
18. Kitani, H., T. Kuroda, A. Moriguchi, K. Hikida, H. Ao, Y. Yokoyama, F. Hirayama, and Y. Ikeda. 1996. Novel 7-substituted-fluoroquinolones as potent antibacterial agents: synthesis and structure-activity relationships, abstr. F-190, p. 146. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
19. Lettieri, J. T., M. C. Rogge, L. Kaiser, R. M. Echols, and A. H. Heller. 1992. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob. Agents Chemother. 36:993-996.
20. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. Piddock, L. J. 1994. New quinolones and gram-positive bacteria. Antimicrob. Agents Chemother. 38:163-169.
22. Sanders, C. C., W. E. Sanders, Jr., and K. S. Thomson. 1995. Fluoroquinolone resistance in staphylococci: new challenges. Eur. J. Clin. Microbiol. Infect. Dis. 14(Suppl. 1):6-11.
23. Shalit, L., S. A. Beerger, A. Gorea, and H. Frierman. 1989. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates on a general hospital. Antimicrob. Agents Chemother. 33:593-594.
24. Tanaka, M., Y. X. Zhang, H. Ishida, K. Sato, and I. Hayakawa. 1995. Mechanisms of 4-quinolone resistance in quinolone-resistant and methicillin-resistant Staphylococcus aureus isolates from Japan and China. J. Med. Microbiol. 42:214-219.
25. Tomasz, A., S. Nachman, and H. Leaf. 1991. Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci. Antimicrob. Agents Chemother. 35:124-129.
26. Wolfson, J. S., and D. C. Hooper. 1989. Fluoroquinolone antimicrobial agents. Clin. Microbiol. Rev. 2:378-424.
27. Yokoyama, Y., M. Morimoto, E. Iwao, K. Yamamoto, K. Honjo, F. Hyrayama, and Y. Ikeda. 1995. Y-688, a new fluoroquinolone with high activity against quinolone-resistant gram-positive bacteria, abstr. F-191, p. 146. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC.
28. Yoshida, H., M. Bogaki, S. Nakamura, K. Ubukata, and M. Konno. 1990. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J. Bacteriol. 172:6942-6949.